-       Report 
- July 2025
-  184 Pages 
- Global 
   From       €4138EUR$4,650USD£3,642GBP 
          -       Report 
- August 2025
-  150 Pages 
- Global 
   From       €5295EUR$5,950USD£4,661GBP 
          -       Report 
- October 2025
-  150 Pages 
- Global 
   From       €5206EUR$5,850USD£4,582GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €3995EUR$4,490USD£3,517GBP 
            -       Clinical Trials 
- April 2025
-  180 Pages 
- Global 
   From       €2136EUR$2,400USD£1,880GBP 
      €2670EUR$3,000USD£2,350GBP 
           From       €4360EUR$4,900USD£3,838GBP 
          -       Report 
- May 2025
-  181 Pages 
- Global 
   From       €4004EUR$4,500USD£3,525GBP 
          -       Report 
- June 2025
-  400 Pages 
- Global 
   From       €4404EUR$4,949USD£3,877GBP 
            -       Report 
- August 2025
-  194 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- August 2025
-  191 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- August 2025
-  195 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
          -       Report 
- May 2025
-  100 Pages 
- Global 
   From       €5295EUR$5,950USD£4,661GBP 
          -       Report 
- May 2025
-  100 Pages 
- Global 
   From       €5295EUR$5,950USD£4,661GBP 
            -       Report 
- October 2025
-  186 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- October 2025
-  188 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- August 2025
-  182 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
            -       Report 
- August 2025
-  195 Pages 
- Global 
   From       €3155EUR$3,545USD£2,777GBP 
      €3505EUR$3,939USD£3,085GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €3995EUR$4,490USD£3,517GBP 
          -       Report 
- April 2025
-  250 Pages 
- Global 
   From       €3995EUR$4,490USD£3,517GBP 
            -       Clinical Trials 
- April 2025
-  60 Pages 
- Global 
   From       €1068EUR$1,200USD£940GBP 
      €1335EUR$1,500USD£1,175GBP 
       
      The Rheumatoid Arthritis Drug market is a subset of the Immune Disorders Drugs market. It is composed of drugs used to treat rheumatoid arthritis, an autoimmune disorder that causes inflammation of the joints. These drugs are used to reduce inflammation, pain, and stiffness, as well as to prevent joint damage. They can be divided into two categories: disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers (BRMs). DMARDs are used to slow the progression of the disease, while    BRMs are used to reduce inflammation and pain.
The Rheumatoid Arthritis Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less   Read more